|
THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING IMMUNOMODULATORY DRUGS |
|---|---|
| รหัสดีโอไอ | |
| Creator | Thaksin Jansing |
| Title | THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING IMMUNOMODULATORY DRUGS |
| Publisher | Faculty of pharmacy, Silpakorn University |
| Publication Year | 2563 |
| Journal Title | Thai Bulletin of Pharmaceutical Sciences |
| Journal Vol. | 15 |
| Journal No. | 1(January-December)2020 |
| Page no. | 49-65 |
| Keyword | thromboprophylaxis, venous thromboembolism, multiple myeloma, immunomodulatory drugs |
| URL Website | https://li01.tci-thaijo.org/index.php/TBPS |
| ISSN | 2586-8659 |
| Abstract | Multiple myeloma (MM) has been associated with an increase in the risk of venous thromboembolism (VTE) and death. Several risk factors of VTE include patients, diseases, and treatments such as patients receiving immunomodulatory drugs (IMiDs) in combination with high doses of dexamethasone or chemotherapy. The thromboprophylaxis protocols depend on risk stratifications. Patients with a standard risk of VTE are given 81-325 mg of aspirin daily. However, patients who are at higher risk are given a daily dose of low-molecular-weight heparins/LMWH (enoxaparin 40 mg), subcutaneously or dose-adjusted warfarin that has a target INR of 2.0-3.0. Medication is given for a minimum of 4-6 months or it can be given in combination with IMiDs during treatment for MM. Importantly, risk assessment for VTE and bleeding should be regularly monitored. |
